Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B.
- DOI
- 10.1016/j.jhepr.2023.100847
- Published
- 2023 Oct
- Container
- JHEP reports : innovation in hepatology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jhepr.2023.100847,
title = {Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B.},
author = {Lim YS and Chan HLY and Ahn SH and Seto WK and Ning Q and Agarwal K and Janssen HLA and Pan CQ and Chuang WL and Izumi N and Fung S and Shalimar and Brunetto M and Hui AJ and Chang TT and Lim SG and Abramov F and Flaherty JF and Wang H and Yee LJ and Kao JH and Gane E and Hou J and Buti M},
year = {2023},
journal = {JHEP reports : innovation in hepatology},
doi = {10.1016/j.jhepr.2023.100847},
url = {https://doi.org/10.1016/j.jhepr.2023.100847}
}RIS
TY - JOUR TI - Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B. AU - Lim YS AU - Chan HLY AU - Ahn SH AU - Seto WK AU - Ning Q AU - Agarwal K AU - Janssen HLA AU - Pan CQ AU - Chuang WL AU - Izumi N AU - Fung S AU - Shalimar AU - Brunetto M AU - Hui AJ AU - Chang TT AU - Lim SG AU - Abramov F AU - Flaherty JF AU - Wang H AU - Yee LJ AU - Kao JH AU - Gane E AU - Hou J AU - Buti M PY - 2023 JO - JHEP reports : innovation in hepatology DO - 10.1016/j.jhepr.2023.100847 UR - https://doi.org/10.1016/j.jhepr.2023.100847 ER -
APA
YS, L., HLY, C., SH, A., WK, S., Q, N., K, A., HLA, J., CQ, P., WL, C., N, I., S, F., Shalimar, M, B., AJ, H., TT, C., SG, L., F, A., JF, F., H, W., LJ, Y., JH, K., E, G., J, H., & M, B. (2023). Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B.. JHEP reports : innovation in hepatology. https://doi.org/10.1016/j.jhepr.2023.100847
Source records
- pubmed · retrieved 2026-09-26T22:57:03.793Z